A Phase 2A Dose-Escalation Study of the Safety, Tolerability, Pharmacokinetics and Haemodynamic Effects of BMS-986231 in Hospitalized Patients with Heart Failure with Reduced Ejection Fraction

BMS-986231 demonstrated a favourable safety and haemodynamic profile in patients hospitalized with advanced heart failure. Based on preclinical data and these study's findings, it is possible that the haemodynamic benefits may be mediated by inotropic and/or lusitropic as well as vasodilatory effects. The therapeutic potential of BMS-986231 should be further assessed in patients with heart failure.